Alternatively, bladder cancer GEM (genetically engineered mouse) models that use the mouse Uroplakin II (UpkII) promoter (proteins constituting the major differentiation products of the urothelium) [88] can be employed to assess the efficacy of preventive or therapeutic strategies targeting different stages of bladder cancer development. The gene discussed is UPK2; the disease is urinary bladder carcinoma.